- Long-term follow-up of the VOYAGE 1 and VOYAGE 2 trials suggests that guselkumab (TREMFYA) is associated with no new safety concerns in patients with moderate to severe psoriasis.
Why this matters
- Guselkumab appears appropriate for long-term use, and patients can safely transition from adalimumab.
- Through week 52, patients treated with guselkumab and adalimumab experienced 262.45 and 328.28 adverse events (AEs) per 100 patient-years (PY), respectively:
- 6.20 and 7.77 serious AEs/100 PY, respectively.
- 1.22 and 1.79 serious infections/100 PY, respectively.
- Through week 100, patients treated with guselkumab experienced 210.41 AEs/100 PY:
- 6.29 serious AEs/100 PY.
- 1.06 serious infections/100 PY.
- After crossover to guselkumab, patients originally treated with adalimumab experienced 160.15 AEs/100 PY:
- 4.44 serious AEs/100 PY.
- 0 serious infections/100 PY.
- 1826 patients: 422 who received placebo, 823 who received guselkumab, and 581 who received adalimumab at baseline were analyzed for safety outcomes.
- Patients originally receiving adalimumab crossed over to guselkumab at week 52 (VOYAGE 1) and at/after week 28, based on clinical response (VOYAGE 2).
- Funding: Janssen Research & Development, LLC.
- Only a 16-week placebo-controlled period.